Open AccessOroxin B Attenuates Ovariectomy-Induced Bone Loss by Suppressing Osteoclast Formation and Activity
Author(s) -
Jian Huang,
Chen-zhong Wang,
Shun-yi Lu,
Zhe Wang,
Zuoqin Yan
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s328238
Subject(s) - osteoclast , ovariectomized rat , bone resorption , rankl , cathepsin k , osteoporosis , mapk/erk pathway , chemistry , in vivo , endocrinology , medicine , nf κb , bone marrow , in vitro , pharmacology , cancer research , phosphorylation , inflammation , receptor , biology , biochemistry , activator (genetics) , estrogen , microbiology and biotechnology
Osteoclasts are the major players in bone resorption and have always been studied in the prevention and treatment of osteoporosis. Previous studies have confirmed that a variety of flavonoids inhibit osteoporosis and improve bone health mainly through inhibiting osteoclastogenesis. Oroxin B (OB) is a flavonoid compound extracted from traditional Chinese herbal medicine Oroxylum indicum (L.) Vent, exerts potent antitumor and anti-inflammation effect, but its effect on osteoclastogensis remains unknown.